Synovial sarcoma (SS) is molecularly defined by the pathognomonic SS18::SSX fusion, a master epigenetic driver. While NTRK gene fusions are high-priority tissue-agnostic targets for TRK inhibitors like larotrectinib, their co-occurrence with established lineage-defining drivers in sarcomas is exceptionally rare and presents a therapeutic paradox.
For decades, the surgical management of non-small cell lung cancer (NSCLC) has been predominantly guided by anatomical staging. However, this traditional approach often overlooks the “fourth dimension” of cancer biology: time.
The follow up in early breast cancer represented a major challenging in oncology practice. Current guidelines are supported by evidence demonstrating no benefit of intensive surveillance.
Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary cancer programs, databases, recommendations, and guidelines have been implemented within the Italian National Health System and at hospital level.
Hereditary cancer genetics is increasingly recognized as an integral component of cancer care, contributing to treatment, early detection, and risk reduction strategies for patients and their relatives. In this context, several hereditary cancer programs, databases, recommendations, and guidelines have been implemented within the Italian National Health System and at hospital level.
Liquid biopsy has emerged as a valuable tool for detecting therapeutic targets and resistance mechanisms. This study evaluated the analytical performance and clinical utility of TruSight Oncology 500 ctDNA (TSO500) compared to the FDA-approved Guardant360 CDx (G360) in detecting actionable alterations in non-small cell lung cancer (NSCLC) patients progressing on targeted therapies.
Soft tissue and bone sarcomas may carry a considerable symptom burden, which typically worsens in the final weeks of life. To help clarify personalized palliative care needs, we investigated discrepancies in end-of-life management between patients with sarcoma and those with the most common carcinomas.
Accurate preoperative imaging is essential for determining operability, guiding surgical planning, and optimizing outcomes in the treatment of non-small cell lung cancer (NSCLC).
Alectinib, a second-generation ALK inhibitor, is used in first-line and adjuvant treatment for ALK-rearranged NSCLC, and has proven to be both effective and well tolerated. Gastrointestinal (GI) perforation is an extremely rare but potentially life-threatening complication, with only sporadic cases reported in the literature.
Multiparametric Whole-Body Magnetic Resonance Imaging (WB-MRI) may enhance bone metastasis detection in metastatic breast cancer (mBC) patients. We report preliminary results from a prospective clinical trial investigating WB-MRI utility in BC patients with bone-predominant lesions, equivocal imaging findings or oligometastatic disease (OMD).